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Background: The incidence of human papillomavirus (HPV)-associated anal cancer is increasing in men who have
sex with men (MSM). Screening for the presumed cancer precursor, high-grade anal squamous intraepithelial
lesions (HSIL) in a manner analogous to cervical cancer screening has been proposed. Uncertainty remains
regarding anal HPV natural history and the role of anal cytology and high-resolution anoscopy (HRA) as screening
tests. Well-designed cohort studies are required to address these issues.
Methods/design: The SPANC study is a prospective study of the epidemiology of low-risk and high-risk anal HPV
infection and related cytological and histological abnormalities in HIV-negative and HIV-positive homosexual men
aged 35 years and over. The study aims to recruit 600 men from community-based settings in Sydney, Australia.
There are six study visits over three years. At the first five visits men undergo a digital ano-rectal examination
(DARE), an anal “Papanicolaou” (Pap) test for HPV detection, genotyping and anal cytology, followed by HRA and
directed biopsy of any visible abnormalities. The men also complete a behavioural questionnaire before each visit.
Questions include a detailed history of sexual behaviour, of anal symptoms, possible anal cancer risk factors and
validated quality of life and psychosocial questions. Questionnaires are also completed 2 weeks and 3 months
following the provision of test results and include questions on participant experience during the procedure and
post-procedure symptoms, including pain and bleeding in addition to quality of life/ psychosocial outcomes.
Discussion: Recruitment for the study began in September 2010 and will conclude in mid-2015, with follow up
continuing to 2018. Thus far, over 350 men have been recruited from a variety of community-based settings and
are broadly representative of the target screening population. The SPANC study is one of only a small number of
cohort studies globally to perform HPV, cytology and HRA screening on all participants over multiple time points.
The study results will contribute to understanding of the natural history of anal HPV and inform the possible
development of guidelines for implementing anal cancer screening programs in this population.
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More than 80% of squamous cell anal cancers are
caused by infection with high-risk human papilloma-
virus (Hr-HPV), mainly HPV16 [1]. In the general popula-
tion anal cancer is uncommon, with rates of between 1
and 2 cases per 100,000 per year in most settings [2].
However, certain subpopulations are at increased risk of
this disease. These include; 1) women who have had pre-
vious HPV-associated anogenital (i.e. vulval, vaginal or
cervical) HSIL or cancer [3]; 2) people with immune defi-
ciency, including those with HIV infection and organ
transplant recipients [4]; and 3) men who have sex with
men (MSM) [5]. Anal cancer rates are highest in MSM
[6], especially in HIV-positive MSM, with no evidence of
decline in incidence since the introduction of effective
antiretroviral therapy [7].
Prophylactic vaccination against HPV has enormous po-
tential to prevent anal cancer among high-risk populations
in the future [8,9]. However, current adult populations are
unlikely to benefit from this. In view of the increasing
health burden of anal cancer and its biological similarities
to cervical cancer, some researchers have advocated for
the introduction of an anal cancer screening program for
high-risk populations [10]. There is uncertainty though,
regarding anal HPV natural history, especially concerning
rates of progression and regression of the presumed anal
cancer precursor, high-grade squamous intraepithelial
lesions (HSIL). There is ongoing assessment and discus-
sion around the performance of anal cytology. In most
countries, there is a scarcity of specialist clinicians trained
in high resolution anoscopy (HRA). Furthermore, the
safety and efficacy of available treatment options is yet to
be proven in randomised controlled trials [11]. For these
reasons, despite years of advocacy, no national authorities
recommend a cytology-based screening program for anal
cancer in any high-risk population [12].
Little is known about the psychosocial and quality of life
(QoL) impacts of anal cancer screening. The psychological
and QoL burden of anal cancer cytology screening among
homosexual men is especially important since a large
number of men will have abnormalities detected at
screening [13]. In women, there is strong evidence that
psychological wellbeing, QoL and psychosexual health are
negatively affected by the experience of an abnormal cer-
vical screening and/or HPV test result [14]. It is currently
unknown how people will respond to an anal cancer
screening program and research examining the psycho-
social consequences of screening is needed.
The Study of the Prevention of Anal Cancer (SPANC)
is a longitudinal study exploring the epidemiology of
anal HPV infection and related abnormalities among a
community recruited cohort of homosexual men. The
study results will contribute to our understanding of the
natural history of the disease, the psychological well-being and QoL impact and the health-related costs of
anal cancer screening of homosexual men. This paper
describes the main design and methodological aspects of
the study and includes descriptive data on selected base-
line characteristics for the first 350 participants recruited
from September 2010 to the end of July 2013.
Design and methods
Overview of design
SPANC is an ongoing, prospective, cohort study based
in Sydney, Australia. The study follows HIV-negative
and HIV-positive homosexual men aged 35 years and
older at six visits over a period of three years, including
a baseline enrollment visit, four follow-up screening
visits and final visit to discuss all study results. The main
objective of the study is to investigate the epidemiology
of anal HPV infection and related cytological and histo-
logical anal abnormalities in this population. Specifically,
the study aims to 1) determine the prevalence, incidence
and risk factors for anal HPV genotype detection and as-
sociated lesions, 2) investigate rates of clearance and
persistence of anal HPV infection, 3) investigate rates of
progression and regression of intraepithelial anal lesions
and 4) assess the psychosocial/QoL impact of screening
in homosexual men. In addition to the objectives des-
cribed above, a number of sub-studies are nested within
the main study. These include sub-studies on molecular
biomarkers, lesion-specific HPV genotyping using laser
capture microdissection (LCM), HPV serology, immu-
nology, health economics and qualitative studies. Details
of these sub-studies will not be covered in this paper.
The baseline data collection commenced in September
2010 and will conclude when the full study sample of 600
men is enrolled (approximately July 2015). Data from the
baseline phase of the study will be used to investigate the
prevalence of type-specific anal HPV infection and preva-
lence of anal squamous intraepithelial lesions. Results
from the baseline questionnaire will be used to investigate
the demographic, behavioural and clinical determinants
and risk factors for type-specific HPV infection and low
and high-grade anal squamous intraepithelial lesions
(LSIL and HSIL). Additionally, the baseline cytology and
HPV genotyping results will be compared with the final
histological diagnosis to evaluate the value of anal cytology
and HPV genotyping as potential screening tools in a set-
ting where the prevalence of anal HPV and HSIL is very
high [13]. Baseline psychosocial factors will be compared
with post-test questionnaire findings.
Follow-up of participants will continue to 2018. Inci-
dence, persistence, clearance and regression rates of
type-specific HPV infection and associated HSIL will be
calculated and compared between groups with different
behavioural, biological and clinical risk factors. Ad-
ditionally, the impact of screening on men’s physical
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and used to assess the benefits and potential harms of
the screening test.
The study will recruit a total of 600 men with an appro-
ximate 3:2 ratio of HIV-negative to HIV-positive partici-
pants. Interim baseline data will be published on the first
350 participants recruited to the end of July 2013.
Ethics
Ethics approval for the study was first granted on 21 April
2010 by the St Vincent’s Hospital (SVH, Sydney, Australia)
Human Research Ethics Committee (File Number 09/
203). The study is conducted in accordance with the
National Health and Medical Research Council (NHMRC)
National Statement of Ethical Conduct in Human Research
2007 (http://www.nhmrc.gov.au/book/national-statement-
ethical-conduct-human-research), the World Medical As-
sociation Declaration of Helsinki (October 2000) and the
International Conference on Harmonisation Note for Gui-
dance on Good Clinical Practice (ICH-GCP) (http://www.
tga.gov.au/industry/clinical-trials-note-ich13595.htm). Writ-
ten informed consent is obtained from all individuals before
any study-specific procedures are performed.
Study population and recruitment
Obtaining a representative sample of homosexual men is
challenging, as there is no defined population from which
to draw a sample. Therefore, recruitment strategies used
in SPANC are based on previous community-based stu-
dies conducted by the Kirby Institute and are centered on
a number of community-based settings in Sydney. These
include gay community social events and organizations,
referrals from other participants and participants from
previous community-based studies involving homosexual
men at the Kirby Institute. Information regarding the
study is distributed through leaflets and advertisements
on gay community websites and SPANC information
nights. To ensure a diverse population of men is reached,
advertisements are also placed in the local gay press and
the social networking site Facebook.
Eligible participants are men aged 35 years or over who
report sex with another man in their lifetime (any homo-
sexual contact). Participants are excluded if they are un-
able to understand English, unable to attend scheduled
follow-up visits or are unwilling to undergo HRA, have a
bleeding disorder or are on anti-coagulation medications
(except aspirin and other non-steroidal anti-inflammatory
drugs). Men who have previously had an HRA or who
have a history of anal cancer are also excluded from the
study.
Once enrolled, contact with the participants is main-
tained though regular reminder emails, text messages and
telephone calls from SPANC study staff. To maximize
retention and maintain engagement with the cohort,participants receive regular SPANC newsletters containing
information on the progress of the study as well as general
information relevant to the field. The newsletters are also
used to address issues and concerns raised by the partici-
pants at their study visits or in the feedback section of the
follow-up questionnaires.
Study procedures
At each screening visit men undergo a digital ano-rectal
exam (DARE), an anal Pap test for HPV genotyping and
anal cytology, HRA and biopsy of any visible abnor-
malities. Testing for sexually transmitted infections is
performed on blood, urine, throat and rectal samples at all
visits other than the six month visit. All participants
complete audio, computer-assisted, self-administered in-
terviews (ACASI, QDS, Bethesda, MD) at each visit.
Additionally, two home-based self-administered question-
naires are scheduled two weeks and three months after
the provision of cytology and histology results. The study
flow and visit schedule are outlined in Figure 1 and
Table 1. The final home based self-administered question-
naire takes place six months after Visit 5, to assess any
longer term cancer worry and psychological distress that
may be related to anal cancer screening. Two months after
Visit 5, participants undergo a 30–60 minute consultation
with a research clinician (visit #6). At this study visit, the
results of each study visit (#1 - #5), including cytological
and histological assessments and HPV testing, are sum-
marised and explained to participants. In addition, indi-
vidualised evaluation of anal cancer risk based on their
test results, and information about future potential anal
cancer screening options are provided.
Questionnaires
Data collected in the baseline questionnaire (visit #1)
includes data on socio-demographics, predictors of gay
social engagement and community involvement, lifetime
and recent (previous six months) sexual practices, general
health, lifestyle and anal health. At follow-up visits
(#2 - #5) the questions focus on sexual experiences,
general health, lifestyle and anal health issues in the pre-
vious six months. Additional information is sought from
HIV-positive participants at all study visits on clinical
measures such as CD4 T-lymphocyte count, HIV viral
load and AIDS-defining illnesses. Measures of the poten-
tial psychosocial impact of anal screening are collected at
the baseline visit and in the two-week and three-month
(post-visit) questionnaires. The two-week questionnaire
also contains questions on discomfort experienced during
the procedure and post-procedure symptoms, including
pain and bleeding.
An overview of the components of the questionnaire,
including examples of variables and the measures and
scales utilized are provided in Table 2.
Figure 1 Study flow at each study visit.
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Venepuncture
Blood samples are drawn for HIV and syphilis testing.
Participants provide additional, optional consent to have
their blood stored (as serum and cell pellets). HPV geno-
type specific serology may be performed and specimens
may be tested for other potential determinants of anal
cancer risk at a later stage.
Urine and throat swab
Swabs from the tonsillar arch and posterior nasopharynx
are collected for gonorrhoea testing. For urethral gonor-
rhoea and chlamydia testing participants are asked tovoid the first 10 ml of urine into the sterile container
provided.
Digital Ano-Rectal Examination (DARE)
DARE is performed on all participants at each study visit
by a study physician using lubricant mixed with 1% ligno-
caine. Possible abnormalities and their positions in the
anal canal or perineum are recorded on the HRA report
form (See Additional file 1).
Anal pap test collection
Two anal canal samples are collected from all partici-
pants at each study visit. The first is an anal Pap test,
Table 1 Study visit schedule outlining procedures and assessments performed at each visit
Baseline Follow-up (+/− 3 months)
Visit number 1 2 3 4 5 6




Follow up Interview X X X X
Psychological interview X X X X X
Clinical process
Venepuncture X X X X
Digital ano-rectal exam X X X X X
Anal swab X X X X X
Urine sample & throat swab1 X ¶ ¶ ¶
High resolution anoscopy & biopsy X X X X X
Discussion of all study results and anal cancer risk x
Laboratory process
HIV testing2 X ¶ ¶ ¶
Syphilis testing 1 X ¶ ¶ ¶
HPV PCR X X X X X
Anal cytology X X X X X
Histology3 X X X X X
Gonorrhoea and chlamydia testing1 X ¶ ¶ ¶
1Syphilis, anal, pharyngeal and urethral gonorrhoea, and anal and urethral chlamydia testing: participants who reported sexual activity since the last annual visit
undergo anal STI testing at the follow up visit (as indicated by ¶). 2HIV testing: only HIV-negative participants. Follow up testing is performed in HIV-negative men
who report sexual activity since the last HIV test (as indicated by ¶). 3Biopsy and histology: participants with lesions seen at high resolution anoscopy undergo
biopsy for further histological assessment.
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inserted (3-5 cm) into the anal canal by the study clinician,
pressed firmly against the wall of the anal canal and slowly
withdrawn in a spiral fashion over approximately one
minute. Immediately after sampling, the swab is inserted
into a vial containing 20 ml of PreservCyt (Hologic, Inc.,
Marlborough, MA, United States) fixative medium and
mixed vigorously. Specimens are sent to Douglas Hanly
Moir Pathology (DHM, Sydney, Australia) for processing.
Before cytological processing, one fifth (4 mL) of the
PreservCyt sample is transferred into a second vial for
HPV DNA detection and genotyping to avoid cross-
contamination [26]. The remaining sample is used for
cytological analysis. If the anal Pap test is unsatisfactory
for cytological evaluation, a repeat anal collection is per-
formed no less than two weeks from the first. This mini-
mum time requirement is to allow sufficient time for the
anal mucosal cells to regenerate after the initial Pap test.
A second swab (BD ProbeTec sample collection kit,
BD Diagnostics, Sparks, MD, United States) is inserted
(3-5 cm) into the anal canal by the study clinician and
gently rotated, then placed into the sterile transport tube
for testing for gonorrhoea and chlamydia.High Resolution Anoscopy (HRA)
HRA is performed at each study visit following collection
of the anal canal samples. After a visual examination of
the perianal region and perineum, a plastic anoscope
coated with lignocaine-containing lubricant is inserted
into the anal canal and the introducer removed. A gauze
swab soaked in 3% acetic acid is then inserted through the
anoscope and left in the anal canal for one minute, to stain
the anal mucosa. The gauze is then removed and the
anoscope re-inserted. The anal canal is visualised under
high magnification using a colposcope with real-time
video image capturing software (Second Opinion Ver-
sion 7.0, Second Opinion Telemedicine Solutions, Inc.
Torrance, California, USA). Further acetic acid is repea-
tedly applied, followed by Lugol’s iodine to stain for any
macroscopic abnormality [27,28]. Biopsies of visual abnor-
malities suspicious of HPV-related lesions are taken with
mini Tischler forceps and placed into a formalin/saline
solution and sent to DHM for processing and histopatho-
logical assessment. Separate forceps are used for each
lesion, in order to prevent cross contamination.
Following removal of the anoscope, 3% acetic acid is
applied to the perianal skin and the area examined using
Table 2 Summary of the main sections of the baseline and follow up questionnaires
Section Examples of variables Measures and standardized scales
Socio-demographics Age, country of birth, ethnicity, relationship status, accommodation
status, employment status, income
Adapted from the Health in Men [15] and
Positive Health [16] studies
Sexual practices Sexual identity Adapted from Health in Men and Positive
Health studies [15,16]
Age at first receptive anal intercourse: Gay community periodic surveys [17,18]
Number of lifetime insertive and receptive anal partners
(with and without a condom)
Lifetime number of female partners
Preferred position during anal sex (receptive or insertive)
Number of insertive and receptive anal partners
(with and without a condom) in the previous six months
Frequency of fingering, fisting and insertion of toys and other objects
in the previous six months
Gay social
engagement
Time spent with gay/homosexual friends Gay community periodic surveys [19]
Disclosure of sexuality to friends/family
Number of gay friends
Involvement with gay community
Health and lifestyle Smoking status 45 and Up study [20]
Alcohol and drug use
History of health problems (lifetime and in the last month)
History of depression and anxiety
Physical activity
General health
Section Examples of Variables Measures and Standardized Scales
Anal health History and frequency of anal douching Adapted from the Blokes with Anal
Squamous Intraepithelial Lesions (BASIL)





Generic measure of health related quality of life SF36 v2 (Australian) [22]
Disease specific distress associated with diagnosis of SIL Cervical Dysplasia Distress and Screening
questionnaires (modified) [23,24]
Generic measures of distress Distress thermometer [24]
Worry about developing anal cancer Perception of risk of anal cancer Cancer worry [24]





Length of HIV infection Positive Health study [16]
Viral load
Most recent CD4-Tcell count
Nadir CD4-Tcell count
Type of antiretroviral medication
Length of time on antiretroviral medication
History of AIDS associated illness
Procedure related
feedback
Post procedure pain and bleeding
Length of pain and bleeding
Discomfort associated with the procedures
Other Reason for joining study Adapted from Health In Men and positive
Health studies [15,16]
Source of recruitment
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are to be taken, the anoscopist may schedule the partici-
pant to return for peri-anal biopsies at a later visit (within
two weeks of study visit). All peri-anal abnormalities are
biopsied under lignocaine local anaesthesia.
Clinical impressions of intra-anal and peri-anal abnor-
malities and their anatomical positions are recorded on
the HRA report form (See Additional file 1). Quantifica-
tion of the total area of intra-anal and/or peri-anal tissue
affected by HSIL is recorded retrospectively once the
histology results are known using a seven point scale;
1) Single small lesion, 2) < half of one quadrant, 3) ≥ half
of one quadrant but < one quadrant, 4) ≥ one quadrant
but < two quadrants, 5) ≥ two quadrants but < three
quadrants, 6) ≥ three quadrants, 7) circumferential
disease. Additionally, annotations of suspected HSIL le-
sions are taken at the time of the procedure. All reporting
is performed with the knowledge of the participant’s HIV
status. The clinicians are also aware of the participant’s
cytology, and HRA +/− biopsy results from any previous
study visits.
All study anoscopists are required to undergo a formal
training program prior to their involvement with the
study. This training program was adapted from the British
Society for Colposcopy and Cervical Pathology Training
Program [27]. Anoscopists are required to observe at least
25 HRA procedures and then perform at least 50 HRAs
under the direct supervision of an experienced anoscopist.
All cases are recorded in a log book and the results of anal
Pap tests and biopsies reviewed, when they become avai-
lable. Once the anoscopist is deemed competent, they
start performing HRA on their own. If required, they are
able to access advice and clinical support from an expe-
rienced anoscopist on an ongoing basis and the log book
of all procedures is maintained.
A quality assurance program for anoscopists is also in
place. First, each anoscopist’s cytology/histology corre-
lation and number of unsatisfactory Pap tests are sum-
marised quarterly and a meeting of anoscopists is held at
which the data are discussed and any significant diffe-
rences between anoscopists are addressed. Second, a
SPANC multidisciplinary team meeting is held quarterly
involving the study investigators, anoscopists and patholo-
gists. Six to eight cases are covered at each meeting in-
cluding review of HRA images, cytology and histology
slides and results, and HPV results. Each anoscopist pre-
sents their cases and any discordant results are discussed




All anal swabs placed in PreservCyt specimens are tested
for HPV DNA using the Roche LINEAR ARRAY(LA) HPV genotyping test (Roche Molecular Systems,
Alameda, CA, United States). DNA is extracted with
the automated MagNA Pure isolation and purification
system (Roche Molecular Systems) by a modified pro-
tocol using 1 ml aliquots of PreservCyt specimens as
described previously [29]. The LA HPV genotyping test
involves PCR amplification of a 450 bp region of the
HPV L1 gene and allows for the identification of 37
HPV genotypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42,
45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68,
69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 (HPV 82v sub-
type), and CP6108 (HPV 89) as well as amplification of
265 bp region of the human ß-globin gene, serving as an
internal control. As an in-house modification, samples
that produced a negative internal control are retested
with ½ the volume of eluted DNA in order to reduce the
inhibition due to high bacterial DNA content in those
samples. In addition, due to possible cross-reactivity of
the HPV-52 probe with types 33, 35, and 58 amplicons,
samples positive for one or more of HPV-33, 35, and 58
probes are further tested using a real-time PCR assay
with an HPV-52 specific hydrolysis probe to rule out
presence of HPV 52 in addition to those types [30].
Syphilis testing
A screening enzyme immunoassay (EIA; ICE syphilis,
Murex Biotech Ltd, Dartford, United Kingdom) is used to
test for syphilis. Positive screening results are confirmed
with the Treponema pallidum particle agglutination assay
and/or the fluorescent treponemal antibody absorption
test. The rapid plasma reagin (RPR) test is used on those
with confirmed syphilis to assist clinical staging and to
detect re-infection. All participants are tested for syphilis
at the baseline visit. At visits 3, 4 and 5, serology is
performed on those participants who have previously
tested negative for syphilis and report sexual activity since
the last visit. In participants with confirmed syphilis at any
prior visit, only RPR is performed.
HIV testing
HIV testing is performed at baseline on all participants who
report their HIV status to be negative, using the AxSYM
HIV antigen/antibody Combo (Abbott Diagnostics, Abbott
Park, IL, United States). Positive results are confirmed by
a western blot assay. HIV testing is performed at visits 3,
4 and 5, on those HIV-negative participants who report
sexual activity since the last visit.
Gonorrhoea and chlamydia testing
All baseline samples are tested for gonorrhoea and chla-
mydia by strand displacement amplification (SDA) using
the BD ProbeTec assay (BD Diagnostics, Sparks MD).
Positive samples undergo a supplementary nucleic acid
amplification assay to confirm the diagnosis. Follow up
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pants who report sexual activity since the last visit.
Cytology and histopathology
The laboratory reporting cytological and histopatho-
logical results is a specialist gynaecological unit opera-
ting within a large private general pathology laboratory
in Sydney, Australia. The gynaecological unit reports
more than 250 000 cervical cytology specimens (conven-
tional and liquid-based slides) per year and more than
12 000 gynaecological surgical specimens per year. Three
anatomical pathologists, each with more than 15 years’
experience in gynaecological pathology, are involved in
the study. The number of cytologists and pathologists
involved were limited in order to enhance reproduci-
bility of reporting. Prior to commencement of the study,
a pathologist and a cytologist prepared a teaching ma-
nual based on available literature and assembled a set of
teaching slides, drawn from previous smaller studies of
anal canal lesions. All participating staff undertook trai-
ning based on these materials.
Cytopathology
Prior to processing for cytology, a 4 ml aliquot is removed
from the ThinPrep vial (total sample volume 20 ml) under
sterile conditions. This aliquot is forwarded to Royal
Women’s Hospital Molecular Microbiology laboratory
(Melbourne, Australia) for HPV testing. The remainder of
the sample is processed using a ThinPrep 2000 processor
(Hologic Inc.,Marlborough, MA, United States) to pro-
duce a TP slide (Hologic Inc., Marlborough, MA, United
States), which is then stained with the ThinPrep pro-
prietary stain (Hologic Inc., Marlborough, MA, United
States). The slide is manually screened by a study cyto-
logist on a standard light microscope. The cytologist com-
pletes a checklist, and creates a provisional report, which
is forwarded with the slide to one of the three study
pathologists for assessment and final reporting. A ‘satisfac-
tory’ slide is defined as having at least 2000 nucleated
squamous cells. The presence or absence of a transform-
ation zone component (at least 10 colorectal glandular
cells and/or squamous metaplastic cells) is recorded but
does not affect determination of satisfactory status. The
Bethesda System (TBS) [31] criteria and terms are used
for cytology reporting. Both the cytologist and pathologist
view the slide blind to any knowledge of previous or
current cytology or histology. Participant date of birth and
study code was available, but no other demographic or
clinical information accompanied the specimen.
Histopathology
Biopsies are received in 10% formal saline and processed
in a routine fashion. Nine levels of each biopsy are pre-
pared. Levels one to three and seven to nine are routinelystained with Haematoxylin and Eosin (H&E) stain. Levels
four to six are prepared on a coated slide and left
unstained for potential use for histochemical staining or
immunostaining. Each case is viewed and reported by one
of the three study pathologists. Every attempt is made to
ensure that a different pathologist views the concurrent
cytology and histology specimens of an individual partici-
pant. At times where this is not possible due to logistical
issues, the study pathologist reports the cytology and
histology at different times. All reporting is done blinded
to clinical factors (other than age) and previous results.
Reporting of the biopsies is performed in accordance
with criteria, terminology and recommendations of the
Lower Anogenital Squamous Terminology (LAST) Project
[32,33]. Details relevant to this study are as follows:
 With respect to non-invasive HPV-related disease,
the following terms are used: Negative for
Squamous Intraepithelial lesion (SIL); Low-grade SIL
(LSIL) and High-grade SIL (HSIL)
– Within the category of HSIL, further subdivision
is performed, into anal intraepithelial neoplasia
(AIN) grade 2 and AIN grade 3. If the biopsy is
from perianal skin the terms perianal
intraepithelial neoplasia (PAIN) 2 and 3 are used.
 Immunostaining for p16 INK4A (p16) is performed
on the unstained spare slide in the following
circumstances:
– To differentiate HSIL from a benign mimic, in
particular, atypical immature metaplasia, but also
inflammatory/reactive changes, tangential
sectioning and partial epithelial denudation.
– When a diagnosis of AIN 2 is proposed, in order
to confirm positive p16 reactivity. If the result is
negative, the lesion is downgraded to LSIL or
negative for SIL.
 Immunostaining for p16 is not used in formulating
diagnoses of straightforward LSIL or straightforward
HSIL – AIN 3.
 Immunostaining for p16 is reported as positive if
there is “continuous strong nuclear or nuclear plus
cytoplasmic staining of the basal cell layer with
extension upwards involving at least one third of the
epithelial thickness” [32,33]. Any other pattern of
staining is regarded as negative.
 Carcinomas are measured in two dimensions and
categorized as “Superficially invasive squamous cell
carcinoma of the anus” (SISSCA) if they meet the
LAST definition.
In addition to the LAST categories above, a decision
was made to sub-categorise LSIL into ‘exophytic’ and ‘flat’,
based on presence or absence respectively of architectural
features of condylomata accuminatum. This decision
Table 3 Socio-demographic, health and lifestyle characteristics
Overall (n=350) HIV positive (n=101) HIV negative (n=249)
n % n % n %
Age
Median (IQR) 49 (42–55) 49 (43–54) 49 (42–56)
Mean (SD) 49.6 (9.3) 48.7 (7.4) 49.9 (9.9)
35 – 44 years 110 31.4 31 30.7 79 31.7
45 – 54 years 143 40.9 47 46.5 96 38.6
55 + years 97 27.7 23 22.8 74 29.7
Country of birth
Australia 234 66.9 72 71.3 162 65.1
New Zealand 21 6.0 6 5.9 15 6.0
Other 95 27.1 23 22.8 72 28.9
Ethnic background
Anglo- Celtic 292 83.4 80 79.2 212 85.1
Aboriginal/Torres Strait 5 1.4 2 2.0 3 1.2
Other 53 15.1 19 18.8 34 13.7
Highest level of education
High School 67 19.1 24 23.8 43 17.3
Tertiary diploma or trade1 84 24.0 28 27.7 56 22.5
Undergraduate degree 86 24.6 28 27.7 58 23.3
Postgraduate degree 113 32.3 21 20.8 92 37.0
Work situation
Full/Part time/self-employed 254 72.6 66 65.4 188 75.5
Unemployed 17 4.9 4 4.0 13 5.2
Retired 57 16.3 22 21.8 35 14.1
Other 2 22 6.3 9 8.9 13 5.2
Weekly income (AU$)
<200 24 6.9 7 6.9 17 6.8
200-499 59 16.9 29 28.7 30 12.1
500-999 61 17.4 23 22.8 38 15.3
1000—1499 61 17.4 12 11.9 49 19.7
≥1500 140 40.0 29 28.7 111 44.6
Missing responses 5 1.4 1 1.0 4 1.6
Currently in a relationship
No 155 44.3 54 53.5 101 40.6
Yes, with male partner 191 54.6 45 44.6 146 58.6
Yes, with female partner 4 1.1 2 2.0 2 0.80
Smoking status
Never 193 55.1 44 43.6 149 59.8
Past 108 30.9 35 34.7 73 29.3
Current 49 14.0 22 21.8 27 10.8
Alcohol consumption
Never 28 8.0 9 8.9 19 7.6
< once a week 81 23.1 33 32.7 48 19.3
1-2 days a week 86 24.6 17 16.8 69 27.7
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Table 3 Socio-demographic, health and lifestyle characteristics (Continued)
3-4 days a week 61 17.4 21 20.8 40 16.1
5-6 days a week 51 14.6 12 11.9 39 15.7
Every day 43 12.3 9 8.9 34 13.7
Recreational drug use in the past 6 months 3
No 95 27.1 19 18.8 76 30.5
Yes 255 72.9 82 81.2 173 69.5
1Technical and further education; 2Other includes: Student, looking after family/friend, disabled/sick, doing unpaid work; 3Drug use includes; marijuana, amyl,
cocaine, ecstasy, speed, crystal methamphetamine, LSD, Special K, heroin, GHB, Viagra, other drugs.
Table 4 Characteristics of HIV-positive men
n %
Years HIV-positive
Median (Range) 16 (8.3-25.3)
Mean (SD) 16.5 (9.0)
Nadir CD4 T cell/μL
Over 500 11 10.9
201 - 500 41 40.6
51 - 200 27 26.7
< 50 21 20.8
Missing 1 1.0
Last CD4 T cell/μL












History of AIDS defining illness
No 70 69.3
Yes 31 30.7
Currently taking any anti-retroviral medication
No 11 10.9
Yes 90 89.1
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may be associated with different HPV types [34,35].
If infection with organisms other than HPV is sus-
pected, appropriate stains are used, for instance im-
munoperoxidase staining for HSV-1 and/or HSV-2 in the
presence of ulceration; and Ziehl-Neelsen staining if gra-
nulomata are present.
Characteristics of the enrolled population
The socio-demographic and lifestyle characteristics of
the first 350 participants are presented in Table 3. Data
are presented for the overall cohort, and stratified by
HIV status. Details of HIV infection (if positive) are
presented in Table 4. Since the study’s commencement
approximately 594 men were contacted by the study
team at least once and approximately 404 were screened
for eligibility. Fifty-four (54) men were excluded because
they did not meet the inclusion criteria. Most common
reasons for exclusion were: too young (26%); unable to
attend scheduled visits due to time/location (26%); have
previously had a HRA (13%); have a history of bleeding
disorders or were on anti-coagulant medication (11%);
have previously been diagnosed with anal cancer (9%),
or other reason (15%). By the end of July 2013, 350 men
of whom 29% (n=101) were HIV-positive were recruited
into the study.
The majority of men were recruited from community
based sources including from gay community events
(32%) or the SPANC website/Facebook (13%). Fifteen
percent (15%) were recruited through friends or part-
ners, 14% through gay organizations or HIV/AIDS orga-
nisations, 11% through gay press and 6% other. In 9% of
cases men were recruited from general practice or sexual
health clinics.
The median age of participants at the time of baseline
interview was 49 years (IQR 42–55). The majority of
participants (67%) were born in Australia and most
(83%) reported Anglo-Celtic ethnic background. The
cohort was highly educated, with 57% of participants
having completed university and 40% reporting a weekly
income of ≥ $1500. Forty-five percent (45%) of men
reported being a past or current cigarette smoker. The
majority of men (92%) consumed alcohol at least once aweek and 73% have used drugs recreationally in the past
6 months (Table 3).
HIV-negative participants in SPANC were generally
more likely to have higher levels of education, higher in-
come, having full or part time employment and higher
alcohol consumption. HIV-positive participants were
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and recreational drug use (Table 3).
Almost all participants self-identified as being homo-
sexual, gay or queer (95.4%) and 4.6% self identified as
bisexual, heterosexual or other. The median age of first
receptive anal intercourse was 21 years (IQR 17–25).
Participants were highly sexually active, with 53% of the
men reporting more than 200 lifetime male sexual part-
ners, and 29% reported having more than 10 male sexual
partners in the previous 6 months. Fifty five percent
(55%) of men reported having unprotected receptive anal
intercourse (URAI) in the previous 6 months. A lifetime
history of anal STIs was also common in this group
being reported by 26%, 21%, 17% and 19% of men for
anal gonorrhea, syphilis, chlamydia and herpes, respec-
tively. Having ever had anal or genital warts was
reported by 43% and 29% of men, respectively. Com-
pared with the HIV-negative, HIV-positive participants
in SPANC reported more lifetime and recent sexual
partners, more frequent URAI, and more past STIs.
Among HIV-positive participants (n=101), the median
time they had been living with HIV was 16 years (IQR
8–25). The majority (84%) had a self-reported CD4
T cell count over 350cells/μL, 79% reported unde-
tectable HIV viral load at their last test and 89% were
on treatment at the time of the baseline interview
(Table 4).
Discussion
SPANC is a prospective longitudinal study of the epi-
demiology of anal HPV and related abnormalities in a
community-based cohort of homosexual men aged 35 and
older in urban Sydney, Australia. Recruitment for the study
began in September 2010 and will conclude in mid-2015,
with follow-up continuing to 2018. By July 2013, approxi-
mately 404 men had been assessed for inclusion and over
350 men have been recruited into the study. SPANC par-
ticipants are recruited from a variety of community-based
settings and can be considered as broadly representative of
the potential target screening population. Men older than
35 years are targeted because anal cancer is still rare at
younger ages [2] and at present, older men are unlikely to
benefit from the implementation of HPV vaccination. Thus
any future community-based screening program would
most likely focus on older homosexual men.
Ultimately, the goal of anal cancer screening will be
to identify those pre-cancerous lesions most likely to
progress to cancer. One of the key issues in HSIL natural
history studies is defining what “high-grade” lesions mean
clinically, and which high-grade lesions are at highest risk
of persistence. It is reasonable to assume that those lesions
that persist over 3 years of follow-up are those that are at
highest risk of progression to cancer. As most HSIL will
never progress to anal cancer [13], identifying risk profilesand correlates of persistence among disease categories is
the first step in establishing a better surrogate endpoint
for anal cancer risk. This is crucial to ensure that only
those at highest risk of progressing to anal cancer receive
treatment.
Strengths and limitations of the study
The strength of the SPANC study is that it is one of only a
small number of cohort studies globally to perform both
cytology and HRA screening on all participants over mul-
tiple time-points, as well as performing HPV DNA geno-
typing. As both anal cytology and HRA are known to
under-diagnose HSIL [36], performing both is critical for
the most accurate research-based estimate of the extent of
disease. Also, extremely detailed sexual behaviour and
other health and lifestyle behaviour data are collected,
which will allow excellent characterisation of associations
of these factors with anal HPV and related lesions.
Currently, there are no widely accepted guidelines on
how anal cancer prevention programs should be im-
plemented. Anal cancer screening only occurs in se-
lected specialised clinics in a small number of countries,
not including Australia. As a result, the efficient conduct
of SPANC has been hindered by significant infrastruc-
ture constraints. Recruitment into the study has been
slower than expected, as clinical and laboratory infra-
structure has had to be developed by the research team.
A shortage of medical personnel trained to perform
HRA and the lack of designated clinic space and faci-
lities for these procedures have been major issues.
The SPANC study is a multidisciplinary collaboration,
bringing together researchers skilled in epidemiology,
behavioural science, nursing, laboratory virology, immu-
nology, sexual health, cytopathology, histopathology, psy-
chology, and health economics. The study results will
provide evidence to inform the possible development of
guidelines for implementing screening programs in this
population. Additionally, the SPANC study is a unique
opportunity to address the lack of resources and infra-
structure in Australia and to establish an advocacy agenda
for additional anal cancer/HSIL diagnostic services for
those populations with recognised higher risks of anal
cancer.
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